Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

108 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Correction to "Discovery of the Bruton's Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 (S)-5-(1-((1-Acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-dihydro-3H-1,2,4-triazol-3-one, by Fragment-Based Drug Design".
Sabat M, Dougan DR, Ermolieff J, Halkowycz P, Knight B, Lawson JD, Scorah N, Smith CR, Taylor ER, Vu P, Wyrick C, Wang H, Balakrishna D, Hixon M, Madakamutil L, McConn D. Sabat M, et al. Among authors: lawson jd. J Med Chem. 2021 Nov 11;64(21):16318. doi: 10.1021/acs.jmedchem.1c01685. Epub 2021 Oct 28. J Med Chem. 2021. PMID: 34708652 No abstract available.
Fragment-based drug discovery of potent and selective MKK3/6 inhibitors.
Adams M, Kobayashi T, Lawson JD, Saitoh M, Shimokawa K, Bigi SV, Hixon MS, Smith CR, Tatamiya T, Goto M, Russo J, Grimshaw CE, Swann S. Adams M, et al. Among authors: lawson jd. Bioorg Med Chem Lett. 2016 Feb 1;26(3):1086-1089. doi: 10.1016/j.bmcl.2015.11.054. Epub 2015 Nov 17. Bioorg Med Chem Lett. 2016. PMID: 26704264
Discovery of potent, reversible MetAP2 inhibitors via fragment based drug discovery and structure based drug design-Part 1.
Cheruvallath Z, Tang M, McBride C, Komandla M, Miura J, Ton-Nu T, Erikson P, Feng J, Farrell P, Lawson JD, Vanderpool D, Wu Y, Dougan DR, Plonowski A, Holub C, Larson C. Cheruvallath Z, et al. Among authors: lawson jd. Bioorg Med Chem Lett. 2016 Jun 15;26(12):2774-2778. doi: 10.1016/j.bmcl.2016.04.073. Epub 2016 Apr 25. Bioorg Med Chem Lett. 2016. PMID: 27155900
Structure-based optimization of 1H-imidazole-2-carboxamides as Axl kinase inhibitors utilizing a Mer mutant surrogate.
Keung W, Boloor A, Brown J, Kiryanov A, Gangloff A, Lawson JD, Skene R, Hoffman I, Atienza J, Kahana J, De Jong R, Farrell P, Balakrishna D, Halkowycz P. Keung W, et al. Among authors: lawson jd. Bioorg Med Chem Lett. 2017 Feb 15;27(4):1099-1104. doi: 10.1016/j.bmcl.2016.12.024. Epub 2016 Dec 20. Bioorg Med Chem Lett. 2017. PMID: 28082036
MET Tyrosine Kinase Inhibition Enhances the Antitumor Efficacy of an HGF Antibody.
Farrell PJ, Matuszkiewicz J, Balakrishna D, Pandya S, Hixon MS, Kamran R, Chu S, Lawson JD, Okada K, Hori A, Mizutani A, Iwata H, de Jong R, Hibner B, Vincent P. Farrell PJ, et al. Among authors: lawson jd. Mol Cancer Ther. 2017 Jul;16(7):1269-1278. doi: 10.1158/1535-7163.MCT-16-0771. Epub 2017 Mar 24. Mol Cancer Ther. 2017. PMID: 28341789
108 results